We searched PubMed and EMBASE from inception through November 2023 using keyword terms remdesivir, hepatotoxicity, COVID-19, and SARS-CoV-2. References of se-lected articles were also screened for additional studies. Studies evaluating the efficacy and safety of remdesivir for the treatment of COVID-19 published in the English language are evaluated. We included randomized controlled trials, observational studies, and systematic reviews evaluating the effectiveness and safety of remdesivir in adult patients hospitalized for the treatment of COVID-19. We excluded studies conducted in the outpatient setting. Hepatotoxicity was defined as the elevation of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than five times the upper limit of normal [66] (link). Per the American College of Gastroenterology guidelines for the evaluation of abnormal liver chemistries, a normal ALT level is considered to range from 29 to 33 IU/L for males and 19 to 25 IU/L for females [76] (link). Levels above these thresholds warrant further evaluation.